Biosyent (TSE:RX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
BioSyent Inc. has reported significant growth in Q2 and H1 of 2024, with record-high Canadian Pharma and Total Company sales, along with increased EBITDA and net income. The company’s strategic initiatives included promoting new brands and in-licensing a promising endocrinology product expected to bolster future revenues.
For further insights into TSE:RX stock, check out TipRanks’ Stock Analysis page.
